DoD P&T Committee Evaluation of the Class SELF MONITORING BLOOD GLUCOSE SYSTEMS are

Hereinafter Referred to as "Class"

And medications in the Pharmaceutical Agents Table are

Hereinafter Referred to as "Agents"

NOTE: The DoD Pharmacy and Therapeutics (P&T) Committee will consider Uniform Formulary Blanket Purchase Agreement (UF BPA) price quotes and Uniform Formulary Voluntary Agreement for TRICARE Retail Pharmacy Refunds (UF VARR) quotes that are contingent upon the number of agents selected for the Uniform Formulary (UF). The Condition Sets and procedures for submitting UF BPA and UF VARR quotes are outlined in the UF BPA Price Quote template (see Appendix A), the UF VARR Quote template (see Appendix A) and under the "UF Price and Refunds Quotes" section below:

Drug Class Description

The DoD Pharmacy and Therapeutics (P&T) Committee intends to evaluate the pharmaceutical agents in this class at the upcoming meeting:

Pharmaceutical Agents Table:

ACCU-CHEK ACTIVE

ACCU-CHEK AVIVA

ACCU-CHEK AVIVA PLUS

ACCU-CHEK COMFORT CURVE

ACCU-CHEK COMPACT

ACCU-CHEK SMARTVIEW

ACCUTREND GLUCOSE

ACURA TEST STRIPS

ADVANCE TEST STRIPS

ADVOCATE DUO

ADVOCATE REDI-CODE

ADVOCATE REDI-CODE DUO

ADVOCATE REDI-CODE+

ADVOCATE TEST STRIP

ASCENSIA AUTODISC

ASSURE 4

ASSURE PLATINUM

ASSURE PRO

BG-STAR

BLOOD GLUCOSE TEST

BLOOD GLUOCSE TEST

BREEZE 2

CARESENS N

CHOICEDM CLARUS TEST STRIPS

CHOICEDM G20

CLEVER CHOICE MICRO TEST STRIP

CLEVER CHOICE PRO

CLEVER CHOICE TALK

CLEVER CHOICE TEST STRIPS

CLEVER CHOICE VOICE+ TST STRIP

CONTOUR

CONTOUR NEXT

CONTROL

CONTROL G3

EASY CHECK TEST STRIP

EASY GLUCO G2

EASY PLUS

EASY PLUS II

EASY STEP

EASY TALK

EASY TOUCH

EASY TRAK

EASYGLUCO

EASYGLUCO PLUS

EASYMAX

EASYMAX 15

EASYPLUS

ECLIPSE

ELEMENT PLUS

ELEMENT TEST STRIPS

EMBRACE

ENVISION

EVENCARE

EVENCARE G2

EVENCARE G3

EVOLUTION TEST STRIPS

EZ SMART

EZ SMART PLUS

FIFTY50 TEST STRIP

FORA D10

FORA D15

FORA D15C

FORA D15G

FORA D15Z

FORA D20

FORA G20

FORA G30A

FORA G71A

FORA G90

FORA TEST STRIP

FORA V10

FORA V12

FORA V20

FORA V22

FORA V30A

FORACARE GD20

FORACARE GD40

FREESTYLE INSULINX

FREESTYLE INSULINX TEST STRIPS

FREESTYLE LITE STRIPS

FREESTYLE LITE TEST STRIPS

FREESTYLE TEST STRIPS

G-4

GE100 BLOOD GLUCOSE TEST

STRIP

GLUCO NAVII

GLUCOCARD 01 SENSOR

GLUCOCARD EXPRESSION

GLUCOCARD VITAL SENSOR

GLUCOCARD X-SENSOR

GLUCOCOM GLUCOSE

GLUCOLAB

GLUCOSE TEST STRIP

GLUCOSTIX

GMATE TEST STRIPS

INFINITY

INFINITY TEST STRIPS

KEYNOTE

LIBERTY TEST STRIPS

MAXIMA

MICRO

MICRODOT

MICRODOT XTRA

MYGLUCOHEALTH

NEUTEK 2TEK TEST STRIPS

NOVA MAX GLUCOSE TEST STRIPS

ON CALL PLUS TEST STRIP

ON CALL VIVID TEST STRIP

ONE TOUCH ULTRA TEST STRIPS

ONE TOUCH VERIO

OPTIUM

OPTIUM EZ

PHARMACIST CHOICE

POCKETCHEM EZ

PRECISION PCX

PRECISION PCX PLUS

PRECISION POINT OF CARE

PRECISION Q-I-D

PRECISION XTRA

PREMIUM BLOOD GLUCOSE TEST

PREMIUM V10

PRODIGY AUTOCODE

PRODIGY NO CODING

QUINTET

QUINTET AC

REFUAH PLUS

RELION CONFIRM-MICRO

RELION PRIME

REVEAL TEST STRIP

RIGHTEST GS100 TEST STRIPS

RIGHTEST GS300 TEST STRIPS

RIGHTEST GS550 TEST STRIPS

SMART CARESENS N

SMARTDIABETES XPRES

SMARTEST TEST

SOLUS V2 TEST STRIPS

SURE EDGE TEST STRIPS

SURECHEK TEST STRIPS

SURESTEP PRO

SURE-TEST EASYPLUS MINI

TELCARE

TEST N'GO

TEST STRIPS

TRUETEST TEST STRIPS

TRUETRACK SMART SYSTEM

TRUETRACK TEST STRIP

ULTIMA

ULTRATRAK

ULTRATRAK ULTIMATE

VICTORY

VOCAL POINT

WAVESENSE AMP

WAVESENSE JAZZ

WAVESENSE PRESTO

Uniform Formulary Considerations

In accordance with 32 CFR 199.21, the P&T Committee will consider the relative clinical effectiveness and relative cost effectiveness of this class in recommending a cost share tier classification (i.e., generic, formulary, or non-formulary) for each agent. There is no minimum or maximum number of agents that may be placed in a given cost share tier classification, though you are instructed to submit multiple quotes based on different conditions (See NOTE above and UF Price and Refunds Quotes section below). Although all the formulations (dosage forms and/or strengths) for a given agent would typically be recommended for the same cost share tier classification, the P&T Committee reserves the right to recommend different cost share tier classifications for a particular formulation of a given agent if the Committee finds significant differences in the clinical effectiveness or cost effectiveness between formulations of a given agent.

Basic Core Formulary (BCF) and Extended Core Formulary (ECF) Considerations

All agents recommended for the generic or formulary cost share tier on the Uniform Formulary will be considered for inclusion on the BCF/ECF. The DoD P&T Committee intentions for the number of BCF/ECF agents in each class and subclass are listed below.

UF BPA and UF VARR Quotes

At this time, DoD will accept price quotes using two different instruments: the UF BPA price quote and the UF VARR quote. Pharmaceutical companies must use the UF BPA price quote for prices that will apply to MTFs and the Mail Order Pharmacy. Pharmaceutical companies must use the UF VARR quote for refunds that will apply to pharmaceuticals dispensed by pharmacies in the Retail Pharmacy Network. While generally similar, each instrument has specific instructions and different submission details.

Price Quotes for MTFs and Mail Order Pharmacy

Price Quote Instrument: UF BPA

The item descriptions and NDC numbers for this class that are covered by FSS contracts are listed in the class utilization dataset. A UF BPA price quote for this Class must include all the NDCs that are included on the FSS contract, unless a request to exclude a specific NDC is approved by the TMA contracting officer in writing as described in the "Instructions for Submitting a BPA Price Quote" on the Uniform Formulary Price and Refund Quote Information Page.

The prices submitted in the UF BPA price quotes will be contingent upon the number of agents selected for the UF and BCF/ECF. Pharmaceutical companies that submit UF BPA price quotes must submit a separate, complete quote for each NDC in the class associated UF BPA Appendix. This will ensure that a company will have a valid price quote for whatever number of agents are recommended for inclusion on the UF and/or BCF/ECF.

The DoD P&T Committee will not accept UF BPA price quotes that are contingent upon market shares.

The DoD reserves the right to exclude specific formulations of a given class or agent from a submitted UF BPA quote based on the recommendations of the P&T Committee and the final decision of the Director, TMA, regarding the UF and BCF/ECF for specific formulations of a given class or agent.

The establishment of a UF BPA with a pharmaceutical company for a generic (multi-source) pharmaceutical agent **does not** establish that pharmaceutical company as the sole source of supply for the pharmaceutical agent. However, in the event of existing Joint DoD/VA contracts, UF

BPA quotes will not be accepted for generic (multi-source) pharmaceutical agents.

Price Quotes for the Retail Pharmacy Network

Price Quote Instrument: UF VARR

The item descriptions and NDC numbers for this class that were utilized in the Retail Pharmacy Network for the last 12 months are listed in the class utilization dataset. A UF VARR quote for an agent is required to include all the NDCs that are included in the FSS NDC list included in the dataset. The DoD will make no attempt to force participating retail pharmacies to dispense specific NDCs.

The proposed refunds submitted in the UF VARR quotes will be contingent upon the number of agents selected for the UF. Pharmaceutical companies that submit UF VARR quotes **must submit** a separate VARR quote for each NDC in the class associated UF VARR Appendix. This will ensure that a company will have a valid price quote for whatever number of agents are recommended for inclusion on the UF.

The DoD P&T Committee will not accept UF VARR quotes that are contingent upon market shares.

The DoD reserves the right to exclude specific formulations of a given class or agent from a submitted UF VARR quote based on the recommendations of the P&T Committee and the final decision of the Director, TMA, regarding the UF and BCF/ECF for specific formulations of a given agent.

UF VARR quotes will not be accepted for generic (multi-source) pharmaceutical agents.

Utilization Data and Determining the Cost of the Class

The **Uniform Formulary Price Quote Information Page** outlines the general approach for determining the cost of this class. Historical utilization data and an example of how an overall weighted average cost per day of therapy may be determined are provided in the utilization dataset.

For the upcoming meeting, it has been determined that none of the agents in the class has an existing price agreement that can be used for determining the cost of a class during the upcoming UF evaluation.

The Evaluation Price for this class will be:

- For the MTF and Mail dispensing venues The lower of:
 - o A UF BPA price quote
 - Big 4 FSS price as listed on the first day of the month preceding the DoD P&T meeting.
- For the Retail dispensing venue- The lower of:
 - UF VARR calculated refund
 - Absent a UF VARR Quote, the current price as of the first day of the month preceding the DoD P&T meeting.
 - If TMA signs a UF VARR higher than the FCP, this does not waive any right of the Department of Defense under 10 U.S.C. 1074g(f).